

## Claims

1. Use of a D- or L-tryptophanyl-ester or its N-acyl derivative for producing a pharmaceutical composition for the prophylaxis and therapy of oxidative pathologic processes in degenerative diseases and/or cancer diseases.
2. Use according to claim 1, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative is the following substance:

tryptophanoctyl-ester, tryptophandodecyl-ester, tryptophanstearyl-ester, tryptophanpalmityl-ester, tryptophanoleyl-ester, N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-ester, N-dodecanoyl-tryptophanpalmityl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester, N-palmitoyl-tryptophanethyl-ester or N-oleoyl-tryptophanethyl-ester.

3. Use according to claim 1, wherein the D- or L-tryptophanethyl-ester or its N-acetyl derivative is tryptophanoctyl-ester, N-oleoyl-tryptophanethyl-ester or N-dodecanoyl-tryptophanethyl-ester.
4. Use according to any one of claims 1 to 3 for the treatment and or prophylaxis of neurodegenerative diseases.
5. Use according to claim 4, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, apoplectic fit or amyotrophic lateral sclerosis.
6. Use according to any one of claims 1 to 3 for the treatment and/or prophylaxis of cataracts.
7. Use according to claim 6, wherein the cataract is Cataracta senilis, Cataracta juvenilis, Cataracta diabetica or Cataracta complicata.
8. Use according to any one of claims 1 to 3 for the treatment and/or prophylaxis of neoplastic diseases.

9. Use according to claim 8, wherein the neoplastic disease is the prostatic carcinoma, the mammary carcinoma, the liver carcinoma, the kidney carcinoma, the colon carcinoma, the gastric carcinoma or the lung (bronchial) carcinoma.
10. Use according to any one of claims 1 to 3 for the treatment and/or prophylaxis of cardiovascular diseases.
11. Use according to claim 10, wherein the cardiovascular disease is arteriosclerosis or a myocardial infarction.
12. Pharmaceutical composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative according to any one of claims 1 to 3 for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases and, optionally, a pharmaceutically acceptable carrier, alone or in combination with other antioxidatively effective pharmaceutical compositions or pharmaceutical compositions used with degenerative and/or cancer diseases.
13. Use for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases comprising the administration of a prophylactic or therapeutic amount of a D- or L-tryptophanyl-ester or its N-acyl derivative according to any one of claims 1 to 3.